drugset / Trial / NCT01014091
Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children
RandomizedParallel-groupTriple-blindPrevention
Summary
The objective of this study is to evaluate the safety and immunogenicity study of GSK Biologicals' pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 9 years.
Timeline
- Start
- 2009-12-01
- Primary completion
- 2011-01-14
- Completion
- 2011-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2340272A | Vaccine | — | Intramuscular |